Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Retatrutide is an unlicensed investigational triple agonist (GLP-1, GIP, glucagon) with no MHRA or EMA marketing authorisation
J Orthop Res 2010;28(9):1155-1161
Its unique "biased" signaling favors GIP receptor activation over GLP-1, which researchers believe contributes to its tolerability profile compared to pure GLP-1 agonists
The injection format ensures complete absorption and predictable pharmacokinetics, meaning your body processes the medication in a reliable, dose-proportional way
Larger losses typically come later, once a therapeutic maintenance dose is reached
US$ 26.02
US$ 25.33
US$ 27.07
